Cumberland Pharmaceuticals Stock Cash And Equivalents
| CPIX Stock | USD 1.37 0.26 23.42% |
Cumberland Pharmaceuticals fundamentals help investors to digest information that contributes to Cumberland Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cumberland Stock. The fundamental analysis module provides a way to measure Cumberland Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cumberland Pharmaceuticals stock.
Cumberland | Cash And Equivalents |
Cumberland Pharmaceuticals Company Cash And Equivalents Analysis
Cumberland Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Cumberland Pharmaceuticals Cash And Equivalents | 18.22 M |
Most of Cumberland Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cumberland Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cumberland Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Cumberland Pharmaceuticals is extremely important. It helps to project a fair market value of Cumberland Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Cumberland Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cumberland Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cumberland Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Cumberland Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Cumberland Pharmaceuticals has 18.22 M in Cash And Equivalents. This is 97.78% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.33% higher than that of the company.
Cumberland Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cumberland Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics of similar companies.Cumberland Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 79.3M | 44.7M | 69.6M | 25.6M | 29.4M | 28.0M | |
| Enterprise Value | 72.6M | 37.1M | 58.6M | 25.7M | 29.6M | 28.1M |
Cumberland Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 23.25 M | ||||
| Shares Outstanding | 14.04 M | ||||
| Shares Owned By Insiders | 44.72 % | ||||
| Shares Owned By Institutions | 14.68 % | ||||
| Number Of Shares Shorted | 89.61 K | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 39.55 M | ||||
| Gross Profit | 32.89 M | ||||
| EBITDA | 153.32 K | ||||
| Net Income | (6.28 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 6.09 M | ||||
| Short Ratio | 1.20 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 91 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 19.24 M | ||||
| Total Asset | 81.78 M | ||||
| Retained Earnings | (17.49 M) | ||||
| Working Capital | 7.73 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
| Net Asset | 81.78 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.